CA3236890A1 - Aldosterone synthase inhibitors for treating chronic kidney disease - Google Patents
Aldosterone synthase inhibitors for treating chronic kidney disease Download PDFInfo
- Publication number
- CA3236890A1 CA3236890A1 CA3236890A CA3236890A CA3236890A1 CA 3236890 A1 CA3236890 A1 CA 3236890A1 CA 3236890 A CA3236890 A CA 3236890A CA 3236890 A CA3236890 A CA 3236890A CA 3236890 A1 CA3236890 A1 CA 3236890A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- alkyl
- formula
- 3alkyl
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163289177P | 2021-12-14 | 2021-12-14 | |
| US63/289,177 | 2021-12-14 | ||
| PCT/US2022/052631 WO2023114170A1 (en) | 2021-12-14 | 2022-12-13 | Aldosterone synthase inhibitors for treating chronic kidney disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3236890A1 true CA3236890A1 (en) | 2023-06-22 |
Family
ID=85151059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3236890A Pending CA3236890A1 (en) | 2021-12-14 | 2022-12-13 | Aldosterone synthase inhibitors for treating chronic kidney disease |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12263157B2 (https=) |
| EP (1) | EP4447961A1 (https=) |
| JP (1) | JP2025500826A (https=) |
| KR (1) | KR20240122521A (https=) |
| CN (1) | CN118401241A (https=) |
| AR (1) | AR127948A1 (https=) |
| AU (1) | AU2022415313A1 (https=) |
| CA (1) | CA3236890A1 (https=) |
| CL (1) | CL2024001470A1 (https=) |
| MX (1) | MX2024007335A (https=) |
| TW (1) | TW202339719A (https=) |
| WO (1) | WO2023114170A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025019546A1 (en) * | 2023-07-17 | 2025-01-23 | Mineralys Therapeutics, Inc. | Methods of treating chronic kidney disease (ckd) or ckd and hypertension with lorundrostat, or a combination of lorundrostat and a sglt2 inhibitor |
| TW202525278A (zh) * | 2023-12-15 | 2025-07-01 | 愛爾蘭商阿斯特捷利康愛爾蘭有限公司 | 治療慢性腎病及高血壓之方法 |
| US20250255851A1 (en) * | 2024-02-14 | 2025-08-14 | Boehringer Ingelheim International Gmbh | Solid forms of an aldosterone synthase inhibitor |
| WO2025190858A1 (en) * | 2024-03-12 | 2025-09-18 | Boehringer Ingelheim International Gmbh | Aldosterone synthase inhibitor for treating heart failure |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994008959A1 (fr) | 1992-10-20 | 1994-04-28 | Taisho Pharmaceutical Co., Ltd. | Derive de prostaglandine |
| AU714033B2 (en) | 1996-07-19 | 1999-12-16 | Nissan Chemical Industries Ltd. | Method for producing purified epoxy compound |
| AR028948A1 (es) | 2000-06-20 | 2003-05-28 | Astrazeneca Ab | Compuestos novedosos |
| ZA200500918B (en) | 2002-10-15 | 2006-12-27 | Otsuka Pharma Co Ltd | 1-substituted 4-nitroimidazole compound and process for producing the same |
| CA2494710C (en) | 2002-10-15 | 2011-05-03 | Otsuka Pharmaceutical Co., Ltd. | 1-substituted-4-nitroimidazole compound and method for preparing the same |
| EP1996588A4 (en) | 2006-03-03 | 2011-10-05 | Torrent Pharmaceuticals Ltd | NEW DUAL ACTION RECEPTOR (DARA) ANTAGONISTS OF ATI AND ETA RECEPTORS |
| EP2001866A2 (en) | 2006-03-29 | 2008-12-17 | Novartis AG | Organic compounds |
| TW200808813A (en) | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
| JP2007297305A (ja) | 2006-04-28 | 2007-11-15 | Daiso Co Ltd | Ｎ−（２，３−エポキシ−２−メチルプロピル）フタルイミドの製造法 |
| CA2660701A1 (en) | 2006-08-25 | 2008-03-06 | Novartis Ag | Fused imidazole derivatives for the treatment of disorders mediated by aldosterone synthase and/or 11-beta-hydroxylase and/or aromatase |
| DE102008022221A1 (de) | 2008-05-06 | 2009-11-12 | Universität des Saarlandes | Inhibitoren der humanen Aldosteronsynthase CYP11B2 |
| WO2010016987A1 (en) | 2008-08-05 | 2010-02-11 | Dow Global Technologies Inc. | Production of solid epoxy resin |
| US20110172217A1 (en) | 2008-09-05 | 2011-07-14 | Shionogi & Co., Ltd. | Ring-fused morpholine derivative having pi3k-inhibiting activity |
| TW201026688A (en) | 2008-10-07 | 2010-07-16 | Schering Corp | Benzodioxan analogues as alpha2C adrenergic receptor modulators |
| WO2010107768A1 (en) | 2009-03-18 | 2010-09-23 | Schering Corporation | Bicyclic compounds as inhibitors of diacylglycerol acyltransferase |
| CA2761009A1 (en) | 2009-05-04 | 2010-11-11 | Plexxikon, Inc. | Compounds and methods for inhibition of renin, and indications therefor |
| NZ596302A (en) | 2009-05-15 | 2014-01-31 | Novartis Ag | Aryl pyridine as aldosterone synthase inhibitors |
| BR112012002214B1 (pt) | 2009-07-31 | 2022-01-25 | Global Alliance For Tb Drug Development | Análogos de nitroimidazooxazina e nitroimidazooxazol, seus usos e composição farmacêutica |
| US8541404B2 (en) | 2009-11-09 | 2013-09-24 | Elexopharm Gmbh | Inhibitors of the human aldosterone synthase CYP11B2 |
| HRP20192323T1 (hr) | 2011-09-15 | 2020-03-20 | F. Hoffmann - La Roche Ag | Novi derivati dihidrokinolin-2-ona |
| US9353081B2 (en) | 2011-09-23 | 2016-05-31 | Hoffmann-La Roche Inc. | Bicyclic dihydroquinoline-2-one derivatives |
| AR088989A1 (es) | 2011-11-30 | 2014-07-23 | Hoffmann La Roche | Derivados biciclicos de dihidroisoquinolin-1-ona |
| HRP20171996T1 (hr) | 2012-04-17 | 2018-02-09 | F. Hoffmann - La Roche Ag | Novi derivati fenil-tetrahidroizokinolina |
| KR102096927B1 (ko) | 2012-09-04 | 2020-04-06 | 삼성전자주식회사 | 제어 채널 엘리먼트들에 대한 어그리게이션 레벨들 개수 조정 장치 및 방법 |
| CA2886117C (en) | 2012-10-05 | 2022-05-31 | Merck Sharp & Dohme Corp. | Indoline compounds and their use as aldosterone synthase inhibitors |
| US8912341B2 (en) | 2013-01-16 | 2014-12-16 | Northwestern University | Enantioselective N-heterocyclic carbene-catalyzed annulation reactions with imidazolidinones |
| KR20150118158A (ko) | 2013-02-22 | 2015-10-21 | 머크 샤프 앤드 돔 코포레이션 | 항당뇨병 비시클릭 화합물 |
| WO2014168861A2 (en) | 2013-04-08 | 2014-10-16 | Cowans Kenneth W | Air supply concepts to improve efficiency of vcrc engines |
| EP4678242A3 (en) | 2013-04-18 | 2026-03-18 | Boehringer Ingelheim International GmbH | Pharmaceutical composition, methods for treating and uses thereof |
| JP6067181B2 (ja) | 2013-04-30 | 2017-01-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | アルドステロンシンターゼ阻害薬 |
| JP6471153B2 (ja) | 2013-10-17 | 2019-02-13 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | アルドステロン合成酵素阻害剤としての新規フェニルジヒドロピリジン誘導体 |
| KR20160100408A (ko) | 2014-01-06 | 2016-08-23 | 리젠 파마슈티컬스 소시에떼 아노님 | 신규한 글루타미나제 저해제 |
| HUE039981T2 (hu) | 2014-07-24 | 2019-02-28 | Boehringer Ingelheim Int | Aldoszteron szintáz inhibitorok |
| WO2016061161A1 (en) | 2014-10-15 | 2016-04-21 | Boehringer Ingelheim International Gmbh | Aldosterone synthase inhibitors |
| WO2016119706A1 (zh) | 2015-01-29 | 2016-08-04 | 南京明德新药研发股份有限公司 | 抗肺结核病的硝基咪唑衍生物 |
| US10155765B2 (en) | 2015-03-12 | 2018-12-18 | Merck Sharp & Dohme Corp. | Carboxamide inhibitors of IRAK4 activity |
| KR20190084096A (ko) | 2016-11-10 | 2019-07-15 | 베링거 인겔하임 인터내셔날 게엠베하 | 약제학적 조성물, 치료 방법 및 이의 용도 |
| CN109053637B (zh) | 2018-08-14 | 2021-03-16 | 杭州泽旺生物科技有限公司 | 尺蠖类性信息素及其中间体的合成方法 |
-
2022
- 2022-12-13 TW TW111147688A patent/TW202339719A/zh unknown
- 2022-12-13 CA CA3236890A patent/CA3236890A1/en active Pending
- 2022-12-13 JP JP2024534762A patent/JP2025500826A/ja active Pending
- 2022-12-13 AR ARP220103413A patent/AR127948A1/es not_active Application Discontinuation
- 2022-12-13 CN CN202280082162.7A patent/CN118401241A/zh active Pending
- 2022-12-13 EP EP22850783.6A patent/EP4447961A1/en active Pending
- 2022-12-13 US US18/079,904 patent/US12263157B2/en active Active
- 2022-12-13 AU AU2022415313A patent/AU2022415313A1/en active Pending
- 2022-12-13 KR KR1020247023466A patent/KR20240122521A/ko active Pending
- 2022-12-13 WO PCT/US2022/052631 patent/WO2023114170A1/en not_active Ceased
- 2022-12-13 MX MX2024007335A patent/MX2024007335A/es unknown
-
2024
- 2024-05-16 CL CL2024001470A patent/CL2024001470A1/es unknown
- 2024-10-29 US US18/930,470 patent/US20250049763A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4447961A1 (en) | 2024-10-23 |
| US12263157B2 (en) | 2025-04-01 |
| AU2022415313A1 (en) | 2024-05-02 |
| US20250049763A1 (en) | 2025-02-13 |
| US20230181538A1 (en) | 2023-06-15 |
| JP2025500826A (ja) | 2025-01-15 |
| MX2024007335A (es) | 2024-06-26 |
| CL2024001470A1 (es) | 2024-09-13 |
| TW202339719A (zh) | 2023-10-16 |
| KR20240122521A (ko) | 2024-08-12 |
| CN118401241A (zh) | 2024-07-26 |
| AR127948A1 (es) | 2024-03-13 |
| WO2023114170A1 (en) | 2023-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12263157B2 (en) | Aldosterone synthase inhibitors for treating chronic kidney disease | |
| JP7525903B2 (ja) | Ｃｘｃｒ４阻害剤の組成物ならびに調製および使用の方法 | |
| JP6013446B2 (ja) | 置換２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリン類の使用 | |
| KR20230028484A (ko) | 암의 치료를 위한 병용 요법 | |
| CN105263497A (zh) | 取代的2,3-二氢咪唑并[1,2-c]喹唑啉治疗淋巴瘤的用途 | |
| KR20140107574A (ko) | Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물 | |
| CN114026072A (zh) | 治疗特发性肺纤维化的方法 | |
| TW201835064A (zh) | 苯并噻吩雌激素受體調節劑 | |
| EP2766015A1 (en) | 2-carboxamide cycloamino urea derivatives in combination with hsp90 inhibitors for the treatment of proliferative diseases | |
| JP2018510869A (ja) | 置換２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリンを含んでいる組合せ | |
| KR20110062943A (ko) | 퀴나졸린 유도체를 유효성분으로 하는 전립선 비대증 예방 또는 치료제 | |
| JP2022502479A (ja) | パーキンソン病および関連疾患の治療のための組成物および使用 | |
| JP2024522008A (ja) | Ｂｃｌ－２阻害剤を使用したｂ細胞悪性腫瘍の治療方法 | |
| JP6247004B2 (ja) | 帯状疱疹関連通の急性期疼痛の予防又は治療剤 | |
| CA3189206A1 (en) | Trpv4 inhibitor as therapeutic agent for ocular disease | |
| JP6952747B2 (ja) | がん処置のためのＴＧＦβ阻害剤およびＣＤＫ阻害剤の組合せ | |
| BR112019020754A2 (pt) | métodos de prevenção ou tratamento de doenças oftalmológicas | |
| US10391101B2 (en) | Derivatives of 7-fluoro-8-chloro-5H-dibenzo [B,E,] [1,4] diazepine and use thereof | |
| WO2024167904A1 (en) | Dosage regimens of estrogen receptor degraders in combination with an mtor inhibitor | |
| WO2022192252A1 (en) | Use of nadolol to treat chronic obstructive pulmonary disease by blockage of the arrestin-2 pathway | |
| US20260021079A1 (en) | Nox inhibitors for use in the treatment of alport syndrome | |
| WO2023064195A1 (en) | Cgrp antagonists for treating trigeminal neuralgia | |
| WO2026090245A1 (en) | Use of ras inhibitors for treating cancer | |
| CN118973583A (zh) | Tyk2抑制剂及其用途 | |
| HK40085364A (en) | Trpv4 inhibitor as therapeutic drug for eye disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251201 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251201 |